膀胱内灌注疗法预防膀胱癌术后复发的效果  

The preventive recurrent results of postoperative in-travesical instlllation therapy in bladder cancer

作　　者：张思孝[1] 李虹[1] 程鸿鸣[1] 张卫东[1] 卢一平[1] 陈宗福[1] 杨宇如[1] 

机构地区：[1]华西医科大学附属第一医院泌尿外科

出　　处：《中华外科杂志》1995年第5期304-306,共3页Chinese Journal of Surgery

摘　　要：１９８５年１月至１９９２年１１月，作者共收治膀胱癌４４１例，其中３５８例行保留膀胱的手术。术后３２１例分别用卡介苗、噻替哌、丝裂霉素Ｃ等作了预防性灌注治疗。３１８例随访了１～７年，全组总复发率为２７．７％，其中卡介苗组１８．１％，噻替哌组３１．２％，丝裂霉素Ｃ组２９．６％，对照组４６．１％。已死亡３２例。本组后一阶段病例肿瘤复发率明显增高，其原因与经尿道膀胱肿瘤切除术适应证掌握过宽，药物疗程方法欠规范及复发病例较多有关。AbstractFrom Jan。 1988 to Nov 1992,441 patients withbladder carcinoma were hospitalized in cur department。385 of them were treated by transurethral resection ofbladder tumor (TURBT) or partial cystectomy。Aftersurgical management, the instillation therapy withBCG, TTP or MMC,etc was used to prevent tumorrecurrence in 321 patients.Follow-up for 1～7 yearsshowed that the mortality rate was 6.9%(22/318),and the tumor recurrence rate in BCG,TTP,MMCand control groups was 18.1%, 31.2%, 29.6%and46.1% respectively. The factors influencing the tumorrecurrence and the prophylactic effect of BCG instilla-tion immunotherapy were discussed。

关 键 词：膀胱肿瘤 灌注疗法 肿瘤复发 预防 外科手术 

分 类 号：R737.140.5[医药卫生—肿瘤]